Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Program And Updated Preliminary Data From Phase 1/2 TARGET-D 101 Dose Escalation And Dose Expansion Trial

Loading news article.

Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Program And Updated Preliminary Data From Phase 1/2 TARGET-D 101 Dose Escalation And Dose Expansion Trial | WAPE

Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Program And Updated Preliminary Data From Phase 1/2 TARGET-D 101 Dose Escalation And Dose Expansion Trial

Article summary

Related companies

Comments —